Drugs that boost the function of a specific type of neurotransmitter receptor may benefit patients with frontotemporal dementia — the second most common type of dementia.
UAB research published in the Journal of Neuroscience offers hope that cycloserine, a drug already approved for use by the FDA, may be an effective therapeutic agent.
FTD is a devastating disease that usually strikes people in their mid to late 50s, who often die within 10 years because there is no effective treatment.Clinical research program to combat chronic fatigue, pain
UAB dental students are glimpsing the future in a surprising place: Birmingham’s Fair Haven Retirement Community.
As they care for residents in the School of Dentistry’s geriatric clinic — the only one of its kind in Alabama — they learn how America’s aging population will shape their careers. While one in four dental patients will be over the age of 65 in the next 25 to 35 years, the elderly currently are underserved in dentistry.
A UAB dentist and student describe the links between oral and overall health among older patients, and share the challenges and joys of caring for them, in UAB Magazine.